Clinical Trial

Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study

Study acronym: PREMYOM1000
Recruiting
View on ClinicalTrials.gov →
Summary
Myopia and high myopia are the leading causes of visual impairment and blindness worldwide. The total number of myopic people globally was estimated to be 2.6 billion in 2020, and it could reach 4.8 billion by 2050 unless preventive interventions are implemented. Strategies to slow the progression of myopia, such as contact lenses, orthokeratology, atropine, and increased time spent outdoors, have shown promising results, although evidence varies depending on the method. However, most research has been conducted in Asia, and there are few studies on ocular growth in myopic children in Europe. Meanwhile, the prevalence of myopia is also increasing significantly in Europe, particularly in France. Understanding the growth of the myopic eye in European children is crucial. Cohort studies of myopic children are scarce and do not always include high-quality imaging. A cohort of myopic children with prospective collection of the best retinal and corneal images, along with ophthalmological exams to detail and model the growth of the myopic eye, will provide valuable insights to enhance our understanding of ocular growth and its inter-individual variability.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-19; most recent amendment 2025-12-03.
Status change: Not Yet Recruiting → Recruiting 2025-05-09
Trial Details
NCT Number NCT06895044
Lead Sponsor Fondation Ophtalmologique Adolphe de Rothschild
Conditions Myopia
Enrollment 1,000 participants
Start Date 2025-04-30
Primary Completion 2033-04-30 (estimated)
Study Completion 2033-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-04